Prediction of response to disease modifying antirheumatic drugs in rheumatoid arthritis

O’Dell, 1996, Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications, N Engl J Med, 334, 1287, 10.1056/NEJM199605163342002 Mottonen, 1999, Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial, Lancet, 353, 1568, 10.1016/S0140-6736(98)08513-4 Boers, 1997, Randomised comparison of step-down prednisolone, methotrexate and sulfasalazine with sulfasalazine alone in early rheumatoid arthritis, Lancet, 350, 309, 10.1016/S0140-6736(97)01300-7 O’Dell, 2002, Treating rheumatoid arthritis early: a window of opportunity?, Arthritis Rheum, 46, 283, 10.1002/art.10092 Landewé, 2002, COBRA combination therapy in patients with early rheumatoid arthritis. Long-term structural benefits of a brief intervention, Arthritis Rheum, 46, 347, 10.1002/art.10083 Genovese, 2002, Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcome, Arthritis Rheum, 46, 1443, 10.1002/art.10308 St Clair, 2004, Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial, Arthritis Rheum, 50, 3432, 10.1002/art.20568 Goekoop-Ruiterman, 2007, Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial, Ann Intern Med, 146, 406, 10.7326/0003-4819-146-6-200703200-00005 Combe, 2004, Should patients with recent-onset polyarthritis receive aggressive treatment?, Joint Bone Spine, 71, 475, 10.1016/j.jbspin.2004.07.005 Gossec, 2004, Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study, Ann Rheum Dis, 63, 675, 10.1136/ard.2003.010611 Verstappen, 2005, A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up, Ann Rheum Dis, 64, 38, 10.1136/ard.2003.014928 Smolen, 2003, A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures, Clin Exp Rheumatol, 21, S209 Hider, 2005, Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis, J Rheumatol, 32, 11 Anderson, 2000, Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration, Arthritis Rheum, 43, 22, 10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9 Morgan, 2003, Contribution of patient related differences to multidrug resistance in rheumatoid arthritis, Ann Rheum Dis, 62, 15, 10.1136/ard.62.1.15 Capell, 1993, Second line (disease modifying) treatment in rheumatoid arthritis. Which drug for which patient?, Ann Rheum Dis, 52, 423, 10.1136/ard.52.6.423 Wolfe, 1991, The effect of age on methotrexate efficacy and toxicity, J Rheumatol, 18, 973 Goëb, 2009, Diagnostic and prognostic usefulness of antibodies to citrullinated peptides, Joint Bone Spine, 76, 343, 10.1016/j.jbspin.2008.12.006 O’Dell, 1998, HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments, Ann Rheum Dis, 57, 209, 10.1136/ard.57.4.209 Pham, 2008, Rituximab (MabThera) therapy and safety management. Clinical tool guide developed by the Rheumatic Diseases & Inflammation Group (club rhumatismes et inflammation, CRI) of the French Society for Rheumatology (société française de rhumatologie, SFR), Joint Bone Spine, 75, S2, 10.1016/S1297-319X(08)73620-0 Ranganathan, 2003, Will pharmacogenomics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?, Ann Rheum Dis, 62, 4, 10.1136/ard.62.1.4 Wolf, 2005, Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis, Ann Rheum Dis, 64, 564, 10.1136/ard.2003.014985 Wessels, 2006, Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis, Arthritis Rheum, 54, 2830, 10.1002/art.22032 Le Loët, 2006, Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology, Ann Rheum Dis, 65, 45, 10.1136/ard.2005.035436 Prunet, 2006, Multiplexed flow cytometric analyses of pro- and anti-inflammatory cytokines in the culture media of oxysterol-treated human monocytic cells and in the sera of atherosclerotic patients, Cytometry A, 69, 359, 10.1002/cyto.a.20272 van der Heijden, 2007, Drud insight: resistance to methotrexate and other disease-modifying antirheumatic drugs-from bench to bedside, Nat Clin Pract Rheumatol, 3, 26, 10.1038/ncprheum0380 Llorente, 2000, Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders Part I: increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome, Joint Bone Spine, 67, 30 Yudoh, 1999, Increased expression of multidrug resistance of P-glycoprotein on Th1 cells correlates with drug resistance in rheumatoid arthritis, Arthritis Rheum, 42, 2014, 10.1002/1529-0131(199909)42:9<2014::AID-ANR32>3.0.CO;2-R Tsujimura, 2008, Overcoming drug resistance induced by P- Glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis, Ann Rheum Dis, 67, 380, 10.1136/ard.2007.070821 Hider, 2005, Drug efflux transporters in rheumatoid arthritis: comment on the article by Kremer, Arthritis Rheum, 52, 670, 10.1002/art.20770 Rudwaleit, 2000, Response to treatment to methotrexate in early rheumatoid arthritis is associated with a decrease of T cells derived tumour necrosis factor a, increase of interleukine 10, and predicted by the initial concentration of interleukine 4, Ann Rheum Dis, 59, 311, 10.1136/ard.59.4.311 Gerli, 1999, Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy, Rheumatology, 38, 1282, 10.1093/rheumatology/38.12.1282 Seitz, 2001, Enhanced in vitro induced production of interleukine 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment, J Rheumatol, 28, 496 Seitz, 2003, Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different American College of Rheumatology response groups to methotrexate, J Rheumatol, 30, 28 Marotte, 2008, Association between the level of circulating bioactive tumor necrosis factor α and the tumor necrosis factor α gene polymorphism at – 308 in patients with rheumatoid arthritis treated with a tumor necrosis factor α inhibitor, Arthritis Rheum, 58, 1258, 10.1002/art.23430 Rooney, 2009, Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression Analysis of a proof-of-concept randomized clinical trial of cytokine blockade, Ann Rheum Dis. Baggott, 2009, Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation, Arthritis Rheum, 60, 2257, 10.1002/art.24685 van der Woude, 2009, Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts, Arthritis Rheum, 60, 2262, 10.1002/art.24661 Hider, 2009, Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis?, Ann Rheum Dis, 69, 57, 10.1136/ard.2008.088237 Wessels, 2007, A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis, Arthritis Rheum, 56, 1765, 10.1002/art.22640